Abstract |
Adjuvant chemotherapy for localised breast cancer aims at reducing the risk of relapse and at increasing overall survival. Decision criteria include tumour burden and biological profile. It appears currently difficult to evaluate the benefit/risk ratio in certain borderline cases, which are more and more frequent. We have evaluated through an anonymous web survey conducted as part of the 2013 Annual Saint-Paul-de-Vence breast conference, the chemotherapy decisions, use of guidelines and level of certainty with decisions in this type of situation through four clinical cases. The survey was proposed to 1,190 French physicians who are directly in charge of breast cancer care, whatever their specialty. Three hundred and fifty-three of them replied, of whom 67 % were oncologists and 15 % surgeons. A significantly heterogeneous decision was observed for two out of four cases, in which 52 and 69 % of the physicians opted for adjuvant chemotherapy, versus 48 and 21 % for abstention respectively. Eighty seven percent of responding physicians used guidelines to guide their decision. These guidelines were regional for 63 %, national for 36 %, local in 21 % and international in 16 % of the cases. The level of certainty varied with clinical cases but not with the physician's specialty, nor type of decision.
|
Authors | Mahmoud Fekih, Thierry Petit, Daniel Zarca, Jean-Marc Guinebretière, Fabrice André, Jean-Yves Pierga, Moïse Namer, Joseph Gligorov, Suzette Delaloge |
Journal | Bulletin du cancer
(Bull Cancer)
Vol. 101
Issue 10
Pg. 918-24
(Oct 2014)
ISSN: 1769-6917 [Electronic] France |
Vernacular Title | Utilisation de référentiels et hétérogénéité décisionnelle des indications de chimiothérapie adjuvante dans les cancers du sein exprimant les récepteurs hormonaux, HER2-négatifs : résultats d'un sondage national en France. |
PMID | 25373691
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Biomarkers, Tumor
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Biomarkers, Tumor
(analysis)
- Breast Neoplasms
(chemistry, drug therapy, pathology)
- Chemotherapy, Adjuvant
(standards)
- Decision Making
- Female
- France
- General Surgery
(statistics & numerical data)
- Guideline Adherence
(statistics & numerical data)
- Health Care Surveys
(statistics & numerical data)
- Humans
- Medical Oncology
(statistics & numerical data)
- Middle Aged
- Neoplasm Recurrence, Local
- Practice Guidelines as Topic
- Radiation Oncology
(statistics & numerical data)
|